Cannabis sativa phytochemicals in cancer therapy: molecular mechanisms and therapeutic potential
Frontiers in Pharmacology · 23.06.2026 · 17
DOI: 10.3389/fphar.2026.1768210 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 23.06.2026. Verfasst von Rosemary Montle und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemical and Biotechnology, Vaal University of Technology, Sebokeng, South Africa. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The therapeutic potential of Cannabis sativa has attracted growing interest in oncology. Its diverse phytochemicals, including cannabinoids, flavonoids, and terpenes, interact with oncogenic signaling pathways and the endocannabinoid system influencing tumour progression and therapeutic responses.
Objective
This review critically evaluates the molecular mechanisms by which Cannabis sativa phytochemicals modulate cancer pathways, with emphasis on apoptosis, oxidative stress regulation, autophagy, angiogenesis, and metastasis. It also explores synergistic and additive interactions among cannabinoids and flavonoids, highlighting their translational relevance. Key Findings Cannabinoids such as Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabigerol (CBG) exhibit pathway-specific effects, including induction of apoptosis, modulation of oxidative stress, and inhibition of angiogenesis. Flavonoids such as cannflavin A, genistein, daidzein, hesperetin, and naringenin exhibit selective cytotoxicity across bladder, breast, melanoma, and pancreatic cancers, often sparing normal tissue. Importantly, phytochemical interactions are not uniformly synergistic; while combinations such as THC and CBD amplify apoptotic signaling, others act additively or antagonistically. Clinical formulations such as Nabiximols provide translational evidence of cannabinoid synergy, although outcomes remain context-dependent.
Conclusion
The disconnect between preclinical efficacy and clinical outcomes underscores critical gaps in dosing strategies, patient selection, and combination regimens. Future research should prioritize mechanistic studies, rational phytochemical combinations, and innovative drug delivery systems. Taken together, Cannabis sativa phytochemicals emerge as promising molecular entities with the potential to reshape integrative oncology, provided their therapeutic promise is matched with rigorous, evidence-based evaluation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Chemical and Biotechnology, Vaal University of Technology, Sebokeng, South Africa.
- College of Agriculture and Environmental Sciences, University of South Africa, Johannesburg, South Africa.
- Department of Biotechnology, Vaal University of Technology, Vanderbijlpark, South Africa.
Zitieren
APA
Montle, R., More, G. K., Takaidza, S., & Mtunzi, F. (2026). Cannabis sativa phytochemicals in cancer therapy: molecular mechanisms and therapeutic potential. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1768210
Vancouver
Montle R, More GK, Takaidza S, Mtunzi F. Cannabis sativa phytochemicals in cancer therapy: molecular mechanisms and therapeutic potential. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1768210
BibTeX
@article{Montle2026,
author = {Montle, Rosemary and More, Garland K and Takaidza, Samkeliso and Mtunzi, Fanyana},
title = {Cannabis sativa phytochemicals in cancer therapy: molecular mechanisms and therapeutic potential},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1768210}
}
EUVIMED